NCT05598723View on ClinicalTrials.gov

BOTOX® vs. XEOMIN® for Chronic Migraine

PHASE3RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

February 24, 2023

Primary Completion Date

February 24, 2026

Study Completion Date

August 24, 2026

Conditions
Chronic Migraine
Interventions
DRUG

IncobotulinumtoxinA (XEOMIN®)

IncobotulinumtoxinA (XEOMIN®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.

DRUG

OnabotulinumtoxinA (BOTOX®)

OnabotulinumtoxinA (BOTOX®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.

Trial Locations (1)

28547

RECRUITING

Naval Medical Center Camp Lejeune, Jacksonville

All Listed Sponsors
lead

Naval Medical Center Camp Lejeune

FED